Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906382 · ClinicalTrials.gov registry record · Early Phase 1
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
A Early Phase 1 study, sponsored by Floor Backes, MD.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT04906382: Clinical Trial Early Phase 1 study, sponsored by Floor Backes, MD.
NCT04906382 is a Early Phase 1 study that was terminated before completion, run by Floor Backes, MD. The registered enrollment target is 2 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04906382, a Early Phase 1 study, was terminated before completion, sponsored by Floor Backes, MD.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage. Mismatch repair deficient tumors (dMMR) may have difficulty repairing DNA mutations during replication that may affect tumor's response to therapy. Immunotherapy with monoclonal antibodies, such as tislelizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tislelizumab may help treat patients with mismatch repair deficient endometrial cancer.
Primary Outcome
1\) Measurements of TCRB clonal expansion in peripheral blood. Measurements of TCR in peripheral blood/-tissue
Interventions
- DRUG Carboplatin
- PROCEDURE Biopsy
- DRUG Paclitaxel
- BIOLOGICAL Tislelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2022-09-01 |
| Phase | Early Phase 1 |
Why NCT04906382 stopped before completion
NCT04906382 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT04906382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04906382 about?
NCT04906382 is a clinical study titled "Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer". This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage. Mismatch repair deficient...
What is the current status of trial NCT04906382?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2021-07-01. Estimated completion is 2022-09-01.
What interventions are being tested in trial NCT04906382?
The interventions under investigation include: Carboplatin (DRUG), Biopsy (PROCEDURE), Paclitaxel (DRUG), Tislelizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04906382?
This trial is sponsored by Floor Backes, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04906382's enrollment target sits among peer trials
2 1973rd of 2000 higher than 16 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI